[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0832069T3 - Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) - Google Patents

Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)

Info

Publication number
DK0832069T3
DK0832069T3 DK95918722T DK95918722T DK0832069T3 DK 0832069 T3 DK0832069 T3 DK 0832069T3 DK 95918722 T DK95918722 T DK 95918722T DK 95918722 T DK95918722 T DK 95918722T DK 0832069 T3 DK0832069 T3 DK 0832069T3
Authority
DK
Denmark
Prior art keywords
apolipoprotein
apo
biphenyl
secretion
inhibitors
Prior art date
Application number
DK95918722T
Other languages
English (en)
Inventor
George J Quallich
George Chang
Peter H Dorff
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/IB1995/000448 external-priority patent/WO1996040640A1/en
Application granted granted Critical
Publication of DK0832069T3 publication Critical patent/DK0832069T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • C07D217/20Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK95918722T 1995-06-07 1995-06-07 Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) DK0832069T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000448 WO1996040640A1 (en) 1995-06-07 1995-06-07 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Publications (1)

Publication Number Publication Date
DK0832069T3 true DK0832069T3 (da) 2003-04-22

Family

ID=11004342

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95918722T DK0832069T3 (da) 1995-06-07 1995-06-07 Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)

Country Status (20)

Country Link
US (1) US5919795A (da)
KR (1) KR100225713B1 (da)
AR (1) AR003424A1 (da)
AT (1) ATE233734T1 (da)
AU (1) AU703493B2 (da)
BG (1) BG62442B1 (da)
CO (1) CO4440626A1 (da)
DE (1) DE69529849T2 (da)
DK (1) DK0832069T3 (da)
DZ (1) DZ2045A1 (da)
IL (3) IL135377A (da)
MA (1) MA23895A1 (da)
MX (1) MX9709914A (da)
OA (1) OA10363A (da)
RO (1) RO116897B1 (da)
RU (1) RU2141478C1 (da)
TN (1) TNSN96085A1 (da)
TR (1) TR199600481A2 (da)
TW (1) TW476756B (da)
YU (1) YU35296A (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1216988A (zh) * 1996-04-30 1999-05-19 辉瑞大药厂 4'-三氟甲基联苯基-2-羧酸[2-(2h-[1,2,4]三唑-3-基甲基)-1,2,3,4-四氢-异喹啉-6-苯]酰胺的制备方法和用于制备它们的中间体
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
ATE295836T1 (de) * 2000-01-18 2005-06-15 Novartis Pharma Gmbh Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US6953671B2 (en) * 2001-02-23 2005-10-11 The Trustees Of Columbia University In The City Of New York Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action
KR100575944B1 (ko) * 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(mtp) 및/또는아포지방단백질 b(apo b)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
WO2003077874A2 (en) * 2002-03-13 2003-09-25 The University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1687299A1 (en) * 2003-11-20 2006-08-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treamtment and/or prevention of disorders modulated by a ppar
JP2007520543A (ja) 2004-02-04 2007-07-26 ファイザー・プロダクツ・インク 置換キノリン化合物
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd 4−(2−メチルフェニル)ベンゾトリフルオライドの製造方法
BRPI0607555A2 (pt) * 2005-04-19 2009-09-15 Surface Logix Inc inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
EA015570B1 (ru) 2006-04-03 2011-10-31 Сантарис Фарма А/С Фармацевтическая композиция
EA201100812A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
AU2007306361A1 (en) * 2006-10-09 2008-04-17 Santaris Pharma A/S RNA antagonist compounds for the modulation of PCSK9
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
US8470791B2 (en) * 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
WO2009027527A2 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
US8440637B2 (en) * 2007-10-04 2013-05-14 Santaris Pharma A/S Combination treatment for the treatment of hepatitis C virus infection
RU2010128543A (ru) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
US8361980B2 (en) * 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
PE20110574A1 (es) * 2008-10-29 2011-08-11 Hoffmann La Roche Derivados de fenilamida y de piridilamida como agonistas de gpbar1
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US9034837B2 (en) * 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
WO2010127212A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
WO2010127208A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
MX2013005479A (es) * 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
JP6255092B2 (ja) 2013-06-27 2017-12-27 ロシュ イノベーション センター コペンハーゲン エーエス Pcsk9を標的とするアンチセンスオリゴマーおよびコンジュゲート

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
CA1248536A (en) * 1982-09-10 1989-01-10 Wellcome Foundation Limited (The) Benzoil acid derivatives
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
BR9714364A (pt) * 1996-11-27 2000-03-21 Pfizer Amidas inibidoras da secreção de apo b/mtp

Also Published As

Publication number Publication date
DE69529849T2 (de) 2003-09-04
DE69529849D1 (de) 2003-04-10
KR970003589A (ko) 1997-01-28
IL135375A (en) 2001-07-24
IL135377A0 (en) 2001-05-20
IL135375A0 (en) 2001-05-20
AU703493B2 (en) 1999-03-25
IL135376A0 (en) 2001-05-20
DZ2045A1 (fr) 2002-07-21
KR100225713B1 (ko) 1999-10-15
MA23895A1 (fr) 1996-12-31
RU2141478C1 (ru) 1999-11-20
AU5478496A (en) 1996-12-19
IL135377A (en) 2001-05-20
BG62442B1 (bg) 1999-11-30
TW476756B (en) 2002-02-21
US5919795A (en) 1999-07-06
TNSN96085A1 (fr) 2005-03-15
YU35296A (sh) 1999-06-15
AR003424A1 (es) 1998-08-05
CO4440626A1 (es) 1997-05-07
ATE233734T1 (de) 2003-03-15
BG100637A (bg) 1997-03-31
TR199600481A2 (tr) 1996-12-21
OA10363A (en) 2001-11-15
MX9709914A (es) 1998-03-31
IL135376A (en) 2001-05-20
RO116897B1 (ro) 2001-07-30

Similar Documents

Publication Publication Date Title
DK0832069T3 (da) Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
FI974440A0 (fi) Bifenyyli-2-karboksyylihappo-tetrahydro-isokinolin-6-yyli-amidijohdannaisia, niiden valmistus ja niiden käyttö mikrosomaalistatriglyseridiä siirtävän proteiinin ja/tai apolipoproteiini B:n (Apo B) erittymiseen inhibiittoreina
NO996491D0 (no) 4-brom- eller 4-iod-fenylaminobenzhydroksamsyre-derivater og deres anvendelse som MEK-inhibitorer
NO941679D0 (no) Gallesyrederivater, fremgangsmåte for fremstilling og deres anvendelse
DK641589D0 (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO20012688D0 (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
DK118791D0 (da) 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner, deres fremstilling og anvendelse som eller til fremstilling af laegemidler
DK326989D0 (da) Alminoalkylaminocarbonylaminodiolaminosyrederivater og deres anvendelse som renininhibitorer
DK1006110T3 (da) Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler
DK0910573T3 (da) Nye aminosyrederivater og deres anvendelse som thrombininhibitorer
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO981522D0 (no) Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister
DK424385D0 (da) Aminobenzopyranoner, deres fremstilling og anvendelse som antipsychotiske og anxiolytiske midler
DK568287D0 (da) Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer
DK398986D0 (da) Aminosyrederivater, fremgangsmaade til deres fremstilling og deres anvendelse
DK123786D0 (da) 4-(3-carboxy-3-diazo-2-oxopropyl)-azetidin-2-oner, deres fremstilling og anvendelse som carbapenemantibiotikummellemprodukter
DK651087A (da) Renininhibitorer iii, deres fremstilling og anvendelse
DK165552C (da) Carboxylsyreestere, deres fremstilling og anvendelse som insecticider
DK513188D0 (da) Aminosyreestre, deres fremstilling og anvendelse som laegemidler
NO991589D0 (no) Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler
NO893525L (no) Amidoaminsalter av alkenylravsyrederivater, fremgangsmaater for deres fremstilling og deres anvendelse som korrosjonsinhibitorer.
DK437287D0 (da) 2,3-dihydrofuranderivater, deres fremstilling og deres anvendelse som mellemprodukter til fremstilling af tetrahydrofuranderivater
DK198287A (da) 3-amino-2-cyanacrylsyreestere, fremgangdsmaade til deres fremstilling og deres anvendelse som hebicider
DK0434020T3 (da) 2,19-Methylenoxy- og 2,19-methylenthiobroforbundne steroider og deres anvendelse som inhibitorer af aromatase og 19-hydroxylase